FLT3 and acute myeloid leukemia: A related TKI, sunitinib (SU112348), inhibits VEGFR1/2 and was developed as an anti-angiogenic drug, yet displays broad activity also against KIT, PDGFRα/β, CSF1R, LCK, and FLT3 (Roskoski, 2007), with potent activity in AML models both in vitro and in vivo (O’Farrell et al., 2003).